Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

SinocellTech Says Anti-CD20 mAb Shows Non-Inferiority to Genetech’s Rituxan

publication date: Aug 16, 2022

Beijing's SinocellTech reported that its anti-CD20 McAb, ripertamab, proved non-inferiority to Genentech’s rituximab (Rituxan) in a China Phase III trial. The trial enrolled 364 patients with primary diffuse large B-cell lymphoma (DLBCL). The Objective Response Rate was 94% in both cohorts with safety events also very similar. In 2018, SinocellTech out-licensed rights for ripertamab to CSPC Pharma in a deal worth up to $98 million plus sales milestones. SinocellTech’s pipeline consists of 23 products including 21 novel differentiated drugs and two biosimilars. More details....

Stock Symbol: (SHA: 688520)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here


BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here


Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here